Effect of Pomegranate Seed Powder on Markers of Metabolic Syndrome

NCT05944029 | Unknown

• 1 other identifier: UVAS
• Study Type: interventional
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

Metabolic syndrome is a public health concern worldwide and in Pakistan as well. Abdominal obesity, hyperglycemia, hypertriglyceridemia, hypertension, and low HDL cholesterol are its hallmarks while pomegranate seed's unique chemical composition has sparked research into the health benefits in same arena as weight control, blood lipid profile changes, and other metabolic disturbances. It's high time to study therapeutic efficiency of Pomegranate seed powder against metabolic syndrome.

Conditions

Metabolic Syndrome

Keywords

Metabolic Syndrome; Hypertension; Obesity; Insulin Resistance; Diabetes; Pomegranate seed powder; Dyslipidemia

Outcome Measures

Primary Outcomes (4)

• Lipid Profile

  The change in Lipid Profile, after consuming Pomegranate seed powder for 7 weeks will be assessed, to look for improvements.

  7 weeks

• Fasting Glucose

  The change in Blood Glucose level, after consuming Pomegranate seed powder for 7 weeks will be assessed, to look for improvements.

  7 weeks

• Blood Pressure

  The change in both systolic and diastolic blood pressure after consuming Pomegranate seed powder for 7 weeks will be assessed, to look for improvements.

  7 weeks

• Weight

  The change in weight, after consuming Pomegranate seed powder for 7 weeks will be assessed, to look for improvements.

  7 weeks

Study Arms (1)

Metabolic syndrome Patients

EXPERIMENTAL

Pomegranate seed powder is administered for alleviating symptoms of metabolic syndrome

Dietary Supplement: Pomegranate seed powder

Interventions

Pomegranate seed powder DIETARY_SUPPLEMENT

10 g powder / day

Also known as: Punica granatum

Metabolic syndrome Patients

Eligibility Criteria

• Age: 30 Years - 60 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• BMI \> 25kg/m2
• Dyslipidemia
• Altered blood glucose level
• Age 30-55 ( male and female)

You may not qualify if:

• Thyroid disorder
• Liver disease
• Kidney disorder
• Cancer etc

Sponsors & Collaborators

• Asif Ali: lead

Study Sites (1)

University of Veterinary and Animal sciences Lahore

Lahore, Punjab Province, 54000, Pakistan

RECRUITING

MeSH Terms

Conditions

Metabolic Syndrome; Hypertension; Obesity; Insulin Resistance; Diabetes Mellitus; Dyslipidemias

Condition Hierarchy (Ancestors)

Hyperinsulinism; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Vascular Diseases; Cardiovascular Diseases; Overweight; Overnutrition; Nutrition Disorders; Body Weight; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Endocrine System Diseases; Lipid Metabolism Disorders

Study Officials

• Dr. Asif Ali, Mphil

  University of Veterinary and Animal Sciences Lahore

  STUDY DIRECTOR

Central Study Contacts

Shahbano Zahid, Mphil

CONTACT

+923095563643; shahbanozahid265@gmail.com

Dr. Asif Ali, PhD

CONTACT

+923017151530; asif.ali@uvas.edu.pk

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: SUPPORTIVE CARE
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Researcher

Model Details: Prospective Clinical Trial

Study Record Dates

• First Submitted: April 11, 2023
• First Posted: July 13, 2023
• Study Start: February 20, 2023
• Primary Completion: July 20, 2023
• Study Completion: August 24, 2023
• Last Updated: July 13, 2023

Record last verified: 2023-07

Data Sharing

• IPD Sharing: Will not share

Locations

PA (1)